Biogen signs agreement to acquire Reata for $7.3bn

31 Jul 2023
www.pharmaceutical-technology.com
Drug ApprovalAcquisition
Biogen signs agreement to acquire Reata for $7.3bn
Preview
Source: Pharmaceutical Technology
Biogen intends to give $172.50 per share in cash to Reata, accompanied by the issuance of term debt. Credit: PictureDesignSwiss/Shutterstock.com.
Biogen has entered a definitive agreement to acquire Reata Pharmaceuticals for an enterprise value of $7.3bn.
Biogen agreed to give $172.50 per share in cash to Reata, accompanied by term debt issuance. The transaction will close in the fourth quarter of 2023.
Recommended Reports
Biogen signs agreement to acquire Reata for $7.3bn
Preview
Source: Pharmaceutical Technology
ReportsPharmaceuticals Industry Deals and Trends in November 2021 - Partnerships, Licensing, Investments... GlobalData
Biogen signs agreement to acquire Reata for $7.3bn
Preview
Source: Pharmaceutical Technology
ReportsPharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q1 2022 - Thematic Research GlobalData
View allCompanies IntelligenceBiogen IncReata Pharmaceuticals IncReata UK LtdView all
Reata is developing therapeutics for treating serious neurologic diseases, one of which is SKYCLARYS (omaveloxolone).
This therapeutic is Reata’s first FDA-approved Friedreich’s ataxia treatment. Its commercial launch is underway in the US while its European regulatory review is ongoing.
Biogen president and CEO Christopher Viehbacher stated: “With extensive expertise in rare disease product development and global commercialisation, as demonstrated by SPINRAZA and the recent launch of QALSODY, we believe Biogen has the foundation in place to accelerate the delivery of SKYCLARYS to patients around the world.
“This is a unique opportunity for Biogen to bolster our near-term growth trajectory, and SKYCLARYS is an excellent complement to our global portfolio of treatments for neuromuscular and rare disease.”
Reata’s acquisition will be slightly dilutive to the non-GAAP [generally accepted accounting principles] diluted earnings per share of Biogen in 2023, including associated transaction costs. It will be neutral in 2024 and significantly accretive from 2025.
Reata is also developing cemdomespib to treat diabetic neuropathic pain. It is an investigational drug and its efficacy and safety have not been yet established by any regulatory authorities.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.